Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor
Switzerland (ots/PRNewswire)
Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) taking place in New Orleans, by Debiopharm and Chugai Pharmaceutical Co., Ltd.
Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying FGFR 1, 2, or 3 genetic alterations. Debiopharm is investigating patient selection criteria with the aim of enabling personalized treatments with Debio 1347/CH5183284 associated with a companion diagnostic.
'We are very pleased to present this latest set of scientific data relating to our FGFR inhibitor, which further reinforces Debiopharm's commitment to the advancement of personalized therapies which have the potential to improve and extend the lives of individuals living with cancer,' said Dr Nigel McCracken, Vice President, Translational Medicine, Debiopharm International SA.
AACR 2016 Abstract
Title
Date AND Time Ndegree(s)
FGFR selective inhibitor Debio
1347 induces tumor
regression in FGFR2-altered gastric
cancer PDX
Wed, April 20
Presented by Debiopharm
International SA 7:30 - 11:00 4784
ERK
signal suppression and sensitivity to
CH5183284/Debio
1347, a selective FGFR inhibitor
Presented by Chugai
Pharmaceutical Co., Ltd. Kamakura Tue, April 19
Japan 8:00 - 12:00 3028
About Debiopharm International SA
Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
For more information, please visit http://www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm International SA Contact Christelle Tur Communication Coordinator christelle.tur@debiopharm.com Tel: +41(0)21-321-01-11 Additional Media Contacts In London Maitland Chiara Valsangiacomo cvalsangiacomo@maitland.co.uk Tel: +44(0)20-7379-5151 Russo Partners, LLC Lena Evans Assistant Vice President lena.evans@russopartnersllc.com Tel: +1-212-845-4262